Send the following on WhatsApp
Continue to ChatSublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder https://unis.ahievran.edu.tr/yayin-detay/2_CZ4pDZW_66/sublingual-buprenorphinenaloxone-treatment-is-not-affected-by-oprm1-a118g-and-bdnf-va66met-polymorphisms-but-alters-the-plasma-beta-endorphin-and-bdnf-levels-in-individuals-with-opioid-use-disorder